Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to greater than 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.
Falini
B
B
Institute of Haematology, University of Perugia, Italy.
Bolognesi
A
A
Flenghi
L
L
Tazzari
P L
PL
Broe
M K
MK
Stein
H
H
Dürkop
H
H
Aversa
F
F
Corneli
P
P
Pizzolo
G
G
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000972:Antineoplastic Agents, Phytogenic; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D017730:Ki-1 Antigen; D009699:N-Glycosyl Hydrolases; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000972:Antineoplastic Agents, Phytogenic; D000922:Immunotoxins; D017730:Ki-1 Antigen; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D009699:N-Glycosyl Hydrolases; D000076985:Saporins